2009
Bone morphogenetic protein‐6 induces the expression of inducible nitric oxide synthase in macrophages
Kwon S, Lee G, Lee J, Kim W, Kim I. Bone morphogenetic protein‐6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology 2009, 128: e758-e765. PMID: 19740337, PMCID: PMC2753926, DOI: 10.1111/j.1365-2567.2009.03079.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingBone Morphogenetic Protein 6Cells, CulturedCycloheximideDactinomycinHumansInterleukin-1betaMacrophages, PeritonealMiceNF-kappa BNitric Oxide Synthase Type IIProtein Synthesis InhibitorsRecombinant ProteinsSignal TransductionSmad ProteinsTumor Necrosis Factor-alphaConceptsBone morphogenetic proteinBMP-6Effects of BMPBone morphogenetic protein 6New protein synthesisMorphogenetic proteinsMurine macrophage cell lineMacrophage cell lineImportant regulatorProtein synthesisProtein 6Cell typesMouse peritoneal macrophagesCell linesActinomycin DNF-kappaBSmadExpressionDose-dependent mannerSynthaseNitric oxide synthasePathwayInductionInducible nitric oxide synthasePeritoneal macrophages
2002
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.Peer-Reviewed Original ResearchConceptsAndrogen-independent human prostate cancer cell linesMixed estrogen agonist/antagonistProstate cancer cell linesHuman prostate cancer cell linesEstrogen agonist/antagonistAgonists/antagonistsCancer cell linesER betaER alphaCell linesDU145 cellsSelective estrogen receptor modulatorsEffects of raloxifeneEstrogen receptor modulatorsPC3M cellsDose-dependent mannerCell deathM raloxifeneWestern blot analysisTime-dependent mannerRaloxifene treatmentReceptor modulatorsBreast cancerPan-caspase inhibitor zVADRaloxifeneRaloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research 2002, 62: 3649-53. PMID: 12097269.Peer-Reviewed Original ResearchConceptsSelective estrogen receptor modulatorsHuman prostate cancer cell line LNCaPAndrogen-independent pathwayProstate cancer cell line LNCaPCancer cell line LNCaPEstrogen receptor modulatorsCell line LNCaPLNCaP cellsER betaReceptor modulatorsAndrogen-sensitive human prostate cancer cell line LNCaPAndrogen-sensitive human prostate cancer cell line LNCaP.Mixed estrogen agonist/antagonistHuman prostate cancer cell line LNCaP.Estrogen agonist/antagonistProstate-specific antigen assaysEffects of raloxifeneProstate cancer cell line LNCaP.Androgen receptor activityPresence of antiandrogensDose-dependent mannerAgonists/antagonistsSelective ER modulatorsAndrogen response elementAntigen assaysRaloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*
Kim H, Kim B, Kim I, Mamura M, Seong H, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid Chloromethyl KetonesAntineoplastic AgentsApoptosisBcl-Associated Death ProteinBcl-X ProteinCarrier ProteinsCaspase 3CaspasesCell DivisionCell MembraneCell NucleusCycloheximideCytochrome c GroupDNA FragmentationDose-Response Relationship, DrugEstrogen Receptor ModulatorsHumansIn Situ Nick-End LabelingMembrane PotentialsMitochondriaPhosphorylationProtein BindingProtein Synthesis InhibitorsProto-Oncogene Proteins c-bcl-2Raloxifene HydrochlorideRetroviridaeTime FactorsTumor Cells, CulturedUrinary Bladder NeoplasmsConceptsMixed estrogen agonist/antagonistTSU-Pr1 cell linesEstrogen agonist/antagonistTSU-Pr1 cellsAgonists/antagonistsCell linesSelective estrogen receptor modulatorsHuman bladder transitional cell carcinoma cell lineEffects of raloxifeneTransitional cell carcinoma cell linesProstate cancer cell linesEstrogen receptor modulatorsCell carcinoma cell linesEstrogen receptor betaHuman bladder cancerDose-dependent mannerEvidence of apoptosisCancer cell linesRaloxifene treatmentCarcinoma cell linesBladder cancerReceptor modulatorsBreast cancerHuman cancer cellsRaloxifene
1996
Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. PMID: 8548772.Peer-Reviewed Original ResearchConceptsProstate cancer cell linesLNCaP cellsProstate cancer cellsType I receptorT beta RCancer cell linesI geneDU145 cellsGenetic changesTGF-beta receptor type III receptorTGF-beta receptor expressionGrowth factor beta 1Beta RCancer cellsHuman prostate cancer cellsProliferation of PC3TGF-beta signalsBlot analysisReceptor type IICell linesDose-dependent mannerSouthern blot analysisType I geneType II receptor